Bureaucratic Infighting Keeps India Pharma Deals Hanging; Mylan’s Agila Buyout Caught In Crossfire?
This article was originally published in PharmAsia News
Executive Summary
Fresh doubts have been raised on whether to allow foreign investments in Indian companies, pitting two powerful government ministries on opposing sides of the battle.